How much funding has Vtesse raised?

Vtesse has raised $42.0M in total funding, most recently a Extension Round.

Who are Vtesse's investors?

Vtesse's investors include New Enterprise Associates, Pfizer Ventures, Bay City Capital, Alexandria Venture Investments.

Where is Vtesse headquartered?

Vtesse is headquartered in Gaithersburg, Maryland, United States.

What industry is Vtesse in?

Vtesse operates in Biotech, Healthcare.

Vtesse

Gaithersburg, United States · Founded 2015 · $42.0M raised

Biotech

Healthcare

Headquarters: Gaithersburg, Maryland
Employees: 1–10
Founded: 2015
Business Model: B2B

Total Funding: $42.0M
Last Round: $17.0M Extension RoundJul 2016
Rounds: 2

About

Vtesse was a rare disease biotechnology company founded around 2014-2015 as a spin-off from NIH/NCATS to develop cyclodextrin (hydroxypropyl-beta-cyclodextrin, VTS-270) as a treatment for Niemann-Pick Type C1 (NPC), a fatal lysosomal storage disorder. The company partnered with NIH researchers to advance the asset through Phase 2b/3 clinical trials. Vtesse secured $25 million in early funding to bankroll NIH-led trials and support its own clinical development program. The company was subsequently acquired by Mallinckrodt Pharmaceuticals, which continued sponsoring the NPC clinical trial.

Summary

Vtesse is a Biotech company based in Gaithersburg, United States, founded in 2015. It has raised $42.0M in total across 2 rounds, most recently a $17.0M Extension Round round in Jul 2016. Investors include New Enterprise Associates, Pfizer Ventures and Bay City Capital.